Source:http://linkedlifedata.com/resource/pubmed/id/19111632
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2009-2-23
|
| pubmed:abstractText |
Rheumatoid arthritis (RA) is an aggressive inflammatory disease in which cytokines/chemokines are thought to recruit leukocytes and induce angiogenesis. The aim of this study is to investigate the effect of flavonol-rich residual layer of hexane fraction from Rhus verniciflua Stokes (RVHxR) and its major compound fisetin on inflammatory cytokine/chemokine production and angiogenic factor in IL-1beta-stimulated RA fibroblast-like synovial cells (FLS) and inflammatory in vivo models. Flavonol-rich RVHxR and its major compound fisetin significantly inhibited IL-1beta-induced FLS proliferation in a dose-dependent manner. Flavonol-rich RVHxR and fisetin significantly decreased IL-1beta-induced inflammatory cytokines (TNF-alpha, interleukin (IL)-6)/chemokines (IL-8, monocyte chemoattractant protein (MCP)-1), and vascular endothelial growth factor (VEGF) of RA FLS. Flavonol-rich RVHxR dose dependently diminished the phophorylation of extracellular signal regulated kinase (ERK) and phospho-Jun NH((2))-terminal kinase (JNK), and its down regulation induced by RVHxR at nontoxic concentrations, while activated the phosphorylation of p38 MAPK in IL-1beta-stimulated RA FLS. The p38 specific inhibitor SB203580 cotreatment with RVHxR effectively increased the expression of VEGF and blocked the phosphorylation of p38 MAPK in IL-1beta-stimulated RA FLS, confirming a critical role of p38 MAPK pathway in angiogenesis inhibition. In experimental inflammation-related models, flavonol-rich RVHxR and fisetin have shown significant anti-inflammatory activities on vascular permeability, leukocyte migration and cellular immunity. Also, flavonol-rich RVHxR and fisetin treatments significantly reduced the incidence and severity of collagen-induced arthritis model. These results suggest that RVHxR and its major compound fisetin have shown potent suppressive effects on some inflammatory cytokines/chemokines and angiogenic factor in IL-1beta-stimulated RA FLS and inflammatory in vivo models. We believe that flavonol-rich RVHxR is a potential therapeutic agent in the treatment of inflammatory and angiogenesis related diseases.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents...,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Flavonoids,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1beta,
http://linkedlifedata.com/resource/pubmed/chemical/Oxazolone,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/SB 203580,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/fisetin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1878-1705
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
268-76
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:19111632-Angiogenesis Inhibitors,
pubmed-meshheading:19111632-Animals,
pubmed-meshheading:19111632-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:19111632-Arthritis, Rheumatoid,
pubmed-meshheading:19111632-Cell Movement,
pubmed-meshheading:19111632-Cell Proliferation,
pubmed-meshheading:19111632-Collagen Type II,
pubmed-meshheading:19111632-Cytokines,
pubmed-meshheading:19111632-Disease Models, Animal,
pubmed-meshheading:19111632-Enzyme Inhibitors,
pubmed-meshheading:19111632-Fibroblasts,
pubmed-meshheading:19111632-Flavonoids,
pubmed-meshheading:19111632-Humans,
pubmed-meshheading:19111632-Hypersensitivity, Delayed,
pubmed-meshheading:19111632-Imidazoles,
pubmed-meshheading:19111632-Interleukin-1beta,
pubmed-meshheading:19111632-Mice,
pubmed-meshheading:19111632-Mice, Inbred DBA,
pubmed-meshheading:19111632-Neovascularization, Pathologic,
pubmed-meshheading:19111632-Oxazolone,
pubmed-meshheading:19111632-Protein Kinases,
pubmed-meshheading:19111632-Pyridines,
pubmed-meshheading:19111632-Rats,
pubmed-meshheading:19111632-Rats, Sprague-Dawley,
pubmed-meshheading:19111632-Rhus,
pubmed-meshheading:19111632-Synovial Membrane,
pubmed-meshheading:19111632-Vascular Endothelial Growth Factor A
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models.
|
| pubmed:affiliation |
Department of Acupuncture & Moxibustion, College of Oriental Medicine, Kyung Hee University, 1 Hoegidong, Dongdaemungu, Seoul 130-701, Republic of Korea.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|